Education
About Us
Working with TipRanks
Follow Us
AnaptysBio Inc (ANAB)
NASDAQ:ANAB
Total Valuation
AnaptysBio has a market cap or net worth of $725.40M. The enterprise value is $575.69M.
Market Cap$725.40M
Enterprise Value$575.69M
Share Statistics
AnaptysBio has 29,380,495 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding29,380,495
Owned by Insiders45.18%
Owned by Institutions0.18%
Financial Efficiency
AnaptysBio’s return on equity (ROE) is -2.05 and return on invested capital (ROIC) is -26.11%.
Return on Equity (ROE)-2.05
Return on Assets (ROA)-0.30
Return on Invested Capital (ROIC)-26.11%
Return on Capital Employed (ROCE)-0.26
Revenue Per Employee671.18K
Profits Per Employee-1.07M
Employee Count136
Asset Turnover0.19
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of AnaptysBio is ―. AnaptysBio’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value5.30
Price to FCF0.00
Price to Operating Cash Flow-7.96
PEG Ratio―
Income Statement
In the last 12 months, AnaptysBio had revenue of 91.28M and earned -145.23M in profits. Earnings per share was -5.12.
Revenue91.28M
Gross Profit88.88M
Operating Income-114.95M
Pretax Income-145.23M
Net Income-145.23M
EBITDA-92.74M
Earnings Per Share (EPS)-5.12
Cash Flow
In the last 12 months, operating cash flow was -101.84M and capital expenditures -366.00K, giving a free cash flow of -102.21M billion.
Operating Cash Flow-101.84M
Free Cash Flow-102.21M
Free Cash Flow per Share-3.48
Dividends & Yields
AnaptysBio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.09
52-Week Price Change-24.47%
50-Day Moving Average24.03
200-Day Moving Average20.64
Relative Strength Index (RSI)42.36
Average Volume (3m)477.66K
Important Dates
AnaptysBio upcoming earnings date is Aug 11, 2025, Before Open (Confirmed).
Last Earnings DateMay 5, 2025
Next Earnings DateAug 11, 2025
Ex-Dividend Date―
Financial Position
AnaptysBio as a current ratio of 9.51, with Debt / Equity ratio of 45.78%
Current Ratio9.51
Quick Ratio9.51
Debt to Market Cap<0.01
Net Debt to EBITDA1.15
Interest Coverage Ratio-2.29
Taxes
In the past 12 months, AnaptysBio has paid 3.00K in taxes.
Income Tax3.00K
Effective Tax Rate>-0.01
Enterprise Valuation
AnaptysBio EV to EBITDA ratio is -2.90, with an EV/FCF ratio of -1.98.
EV to Sales2.94
EV to EBITDA-2.90
EV to Free Cash Flow-1.98
EV to Operating Cash Flow-1.99
Balance Sheet
AnaptysBio has $339.94M in cash and marketable securities with $15.57M in debt, giving a net cash position of -$324.36M billion.
Cash & Marketable Securities$339.94M
Total Debt$15.57M
Net Cash-$324.36M
Net Cash Per Share-$11.04
Tangible Book Value Per Share$2.50
Margins
Gross margin is 98.94%, with operating margin of -125.93%, and net profit margin of -159.10%.
Gross Margin98.94%
Operating Margin-125.93%
Pretax Margin-159.10%
Net Profit Margin-159.10%
EBITDA Margin-101.60%
EBIT Margin-104.23%
Analyst Forecast
The average price target for AnaptysBio is $54.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$54.50
Price Target Upside124.93% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast387.20%
EPS Growth Forecast21.00%